BioInvent is a research-based pharmaceutical company focused on discovery and development of innovative antibody-based drugs against cancer. BioInvent also develops antibody-based drugs in collaboration with partners who finance the development of new drugs and provide BioInvent with the right to milestone payments and royalties on sales.
Bioinvent – antibody drug discovery
BioInvent’s drug development programs are supported by its human antibody development platform. This consists of a proprietary antibody library, n-CoDeR, and in-house technology for the rapid selection, screening and identification of antibodies with excellent affinity and selectivity for targets. BioInvent has a high level of competence in antibody drug discovery, preclinical and clinical development.
BioInvent has developed two patented technology platforms that will enable identification of relevant human antibodies and disease targets – the unique F.I.R.S.T. development tool and the n-CoDeR antibody library, containing completely human antibodies. Basically, drug candidates can be selected that bind very specifically and firmly to their target structures. These technology platforms are used to develop antibody-based drugs in collaboration with its partners as well as in BioInvent’s proprietary projects. In addition, BioInvent offers a cGMP-certified manufacturing facility for the production of antibodies. BioInvent also provides biological and preclinical expertise, primarily in the field of cancer biology and tumour immunology, to both commercial and scientific collaborations.
BioInvent’s business model and technology platform have been validated through numerous partnerships. These include agreements with Bayer Pharma, Daiichi Sankyo, Mitsubishi Tanabe Pharma, Servier and others. Management Team is composed by Michael Oredsson, Björn Frendéus, Per-Anders Johansson and Anna Wickenberg. BioInvent employs around 40 people and is based in Lund (Sweden). The Company was listed on the NASDAQ OMX Stockholm in 2001.
More about Bioinvent : www.bioinvent.se